Fig. 8: IgG glycosylation and serum protein glycation in trial participants.
From: The use of a systems approach to increase NAD+ in human participants
a Changes to IgG glycosylation profiles measured then extrapolated as ‘biological age’ through commercial service (GlycanAge, UK) expressed as difference from baseline at 28 d; mean with 95% CI (n = 24). b Serum protein glycation (Jinfiniti, Augusta, USA) at baseline and 28 d expressed as mean ± SEM (n = 24). *P < 0.05 by Student’s t-test.
